Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zoom
ZM
|
+$806M |
| 2 |
AbbVie
ABBV
|
+$481M |
| 3 |
T-Mobile US
TMUS
|
+$464M |
| 4 |
Kroger
KR
|
+$430M |
| 5 |
Baidu
BIDU
|
+$423M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.35B |
| 2 |
AGN
Allergan plc
AGN
|
+$1.26B |
| 3 |
S
Sprint Corporation
S
|
+$675M |
| 4 |
Amgen
AMGN
|
+$488M |
| 5 |
Humana
HUM
|
+$450M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 23.76% |
| 2 | Technology | 16.41% |
| 3 | Consumer Staples | 10.58% |
| 4 | Consumer Discretionary | 10.12% |
| 5 | Communication Services | 9.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Bristol-Myers Squibb
BMY
$120B
| $2.56B | 2.21% |
43,497,131
-22,494,980
| -34% | -$1.35B |
2016 Q2
16 quarters
|
|
|
NVO
2
Novo Nordisk
NVO
$166B
| $1.88B | 1.62% |
57,419,662
+1,699,210
| +3% | +$54.2M |
2013 Q2
28 quarters
|
|
|
3
AbbVie
ABBV
$472B
| $1.87B | 1.61% |
19,021,869
+5,466,020
| +40% | +$481M |
2018 Q1
9 quarters
|
|
|
4
Zoom
ZM
$27.2B
| $1.84B | 1.59% |
7,256,035
+4,478,495
| +161% | +$806M |
2020 Q1
1 quarter
|
|
5
Chipotle Mexican Grill
CMG
$41.5B
| $1.7B | 1.47% |
80,717,100
-11,245,000
| -12% | -$208M |
2016 Q4
14 quarters
|
|
6
Vertex Pharmaceuticals
VRTX
$127B
| $1.68B | 1.45% |
5,781,332
-1,078,350
| -16% | -$292M |
2017 Q1
13 quarters
|
|
7
VeriSign
VRSN
$26.8B
| $1.51B | 1.31% |
7,310,690
-794,600
| -10% | -$165M |
2013 Q2
28 quarters
|
|
8
Atlassian
TEAM
$50B
| $1.23B | 1.06% |
6,835,013
+400,989
| +6% | +$66.6M |
2016 Q2
16 quarters
|
|
9
Tesla
TSLA
$1.47T
| $1.2B | 1.03% |
16,603,590
+5,091,000
| +44% | +$275M |
2018 Q4
6 quarters
|
|
|
10
Baidu
BIDU
$28.5B
| $1.16B | 1% |
9,663,857
+3,953,814
| +69% | +$423M |
2019 Q3
3 quarters
|
|
11
Palo Alto Networks
PANW
$334B
| $1.15B | 0.99% |
29,941,512
-2,574,594
| -8% | -$90.7M |
2015 Q2
20 quarters
|
|
12
Biogen
BIIB
$32.4B
| $1.05B | 0.9% |
3,905,922
-567,990
| -13% | -$171M |
2018 Q1
9 quarters
|
|
13
Pinduoduo
PDD
$111B
| $957M | 0.83% |
11,150,680
+3,279,206
| +42% | +$197M |
2019 Q2
4 quarters
|
|
14
Target
TGT
$69.6B
| $945M | 0.82% |
7,880,897
+871,738
| +12% | +$99.5M |
2019 Q1
5 quarters
|
|
15
Walmart Inc
WMT
$871B
| $929M | 0.8% |
23,272,842
-6,133,800
| -21% | -$252M |
2018 Q4
6 quarters
|
|
|
16
Humana
HUM
$45.9B
| $902M | 0.78% |
2,327,242
-1,201,900
| -34% | -$450M |
2015 Q2
20 quarters
|
|
17
Monster Beverage
MNST
$85.3B
| $895M | 0.77% |
51,630,360
-2,796,008
| -5% | -$45.6M |
2014 Q1
25 quarters
|
|
|
18
Kroger
KR
$35.6B
| $887M | 0.77% |
26,212,088
+13,242,785
| +102% | +$430M |
2019 Q2
4 quarters
|
|
19
GSK
GSK
$92.5B
| $838M | 0.72% |
16,441,003
-2,020,160
| -11% | -$104M |
2013 Q2
28 quarters
|
|
20
Fortinet
FTNT
$140B
| $820M | 0.71% |
29,868,435
-453,505
| -1% | -$11.4M |
2015 Q3
19 quarters
|
|
21
Newmont
NEM
$120B
| $794M | 0.69% |
12,856,785
+903,598
| +8% | +$53.5M |
2017 Q3
11 quarters
|
|
22
Franco-Nevada
FNV
$46.1B
| $792M | 0.68% |
5,672,083
+767,265
| +16% | +$102M |
2014 Q1
25 quarters
|
|
23
Novartis
NVS
$268B
| $724M | 0.63% |
8,294,608
-196,800
| -2% | -$17M |
2013 Q3
27 quarters
|
|
|
B
24
Barrick Mining
B
$64.9B
| $722M | 0.62% |
26,806,209
+1,673,938
| +7% | +$41.8M |
2014 Q2
24 quarters
|
|
25
eBay
EBAY
$48.4B
| $697M | 0.6% |
13,279,334
+789,463
| +6% | +$33.4M |
2019 Q1
5 quarters
|
|
Similar funds
Renaissance Technologies's Q2 2020 Portfolio in Review
As of Q2 2020, Renaissance Technologies held 3,987 positions worth $116B, up 13% from $103B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Renaissance Technologies withdrew a net $8.24B in Q2 2020, closing 596 positions and reducing 1,365 holdings. Its most notable exit was Allergan plc, an estimated $1.26B position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 24% of assets, down from 26% a quarter earlier, followed by Technology and Consumer Staples.
Against the trend, Renaissance Technologies opened a new position in Uber worth $187M.
- Renaissance Technologies's largest Q2 2020 buy was Uber: 6,030,316 shares worth $187M.
- Renaissance Technologies added most to Zoom in Q2 2020, an estimated $806M increase.
- Renaissance Technologies's biggest Q2 2020 reduction was Bristol-Myers Squibb, cutting an estimated $1.35B.
- Renaissance Technologies fully exited Allergan plc in Q2 2020, selling an estimated $1.26B.
- Renaissance Technologies's ten largest holdings make up 14% of its $116B portfolio in Q2 2020.
- Renaissance Technologies opened 584 new positions and closed 596 in Q2 2020.
- Renaissance Technologies's portfolio value rose 13% quarter-over-quarter to $116B.
Based on Renaissance Technologies's 13F filing for Q2 2020, filed 13 Aug 2020.